Register Login

NEUROCRINE BIOSCIENCES INC (NBIX)

SymbolNBIX
NameNEUROCRINE BIOSCIENCES INC
SectorHEALTH CARE
RegionNorth America
IndustryBiological Products, (No Diagnostic Substances)
Address6027 EDGEWOOD BEND COURT, SAN DIEGO, CA 92130
Telephone(858) 617-7600
Fax—
Email—
Websitehttps://www.neurocrine.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0000914475
Description

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The companys three late stage clinical programs are elagolix which is hormone releasing antagonist for womens health, opicapone which is an inhibitor for parkinsons patients, and ingrezza for tourette syndrome.

Additional info from NASDAQ:
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The companys three late stage clinical programs are elagolix which is hormone releasing antagonist for womens health, opicapone which is an inhibitor for parkinsons patients, and ingrezza for tourette syndrome.

2026-06-09 21:40

Director SHERWIN STEPHEN A 🟡 adjusted position in 25.0K shares (2 derivative) of NEUROCRINE BIOSCIENCES INC (NBIX) at $167.31 ($7.3M) Transaction Date: Jun 05, 2026 | Filing ID: 000006

Read more
2026-06-09 21:34

Onyia Jude 🔴 sold 2.4K shares of NEUROCRINE BIOSCIENCES INC (NBIX) Transaction Date: Jun 05, 2026 | Filing ID: 000014

Read more
2026-06-08 22:07

Director Norwalk Leslie V 🔴 sold 1.2K shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $168.06 Transaction Date: Jun 04, 2026 | Filing ID: 000009

Read more
2026-06-08 20:05

Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients

Read more
2026-06-08 12:30

Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities

Read more
2026-06-04 22:02

Cooke Julie 🟡 adjusted position in 36.9K shares (1 derivative) of NEUROCRINE BIOSCIENCES INC (NBIX) at $158.59 ($9.8M) Transaction Date: Jun 02, 2026 | Filing ID: 000010

Read more
2026-06-04 21:54

Keswani Sanjay Chandru 🟡 adjusted position in 1.7K shares (1 derivative) of NEUROCRINE BIOSCIENCES INC (NBIX) at $154.84 Transaction Date: Jun 02, 2026 | Filing ID: 000004

Read more
2026-06-03 12:30

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

Read more
2026-06-02 22:08

Onyia Jude 🟡 adjusted position in 11.0K shares (1 derivative) of NEUROCRINE BIOSCIENCES INC (NBIX) at $160.25 ($3.6M) Transaction Date: Jun 01, 2026 | Filing ID: 000012

Read more
2026-06-02 22:03

Delaet Ingrid 🟡 adjusted position in 2.3K shares (1 derivative) of NEUROCRINE BIOSCIENCES INC (NBIX) at $156.71 Transaction Date: May 29, 2026 | Filing ID: 000007

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07611786 Development of Healthcare Transition for Patients With Congenital Adrenal Hyper… — Congenital Adrenal Hyperplasia Not_Yet_Recruiting 2026-06-01 2029-07-01 ClinicalTrials.gov
NCT07111988 Valbenazine in Obsessive Compulsive Disorder Phase2 Obsessive-Compulsive Disorder Not_Yet_Recruiting 2026-06-01 2027-12-01 ClinicalTrials.gov
NCT07536269 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in … Phase2 Congenital Adrenal Hyperplasia Not_Yet_Recruiting 2026-04-01 2028-03-01 ClinicalTrials.gov
NCT07288333 Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia Phase2 Schizophrenia Recruiting 2026-02-16 2027-08-01 ClinicalTrials.gov
NCT07365462 Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With… Phase2 Tardive Dyskinesia Recruiting 2026-02-06 2027-03-01 ClinicalTrials.gov
NCT07288320 An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adult… Phase2 Bipolar I Disorder Recruiting 2025-12-24 2028-02-01 ClinicalTrials.gov
NCT07227818 Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia Phase3 Schizophrenia Recruiting 2025-12-16 2029-07-01 ClinicalTrials.gov
NCT07187375 Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With … Phase2 Congenital Adrenal Hyperplasia Recruiting 2025-09-30 2029-10-04 ClinicalTrials.gov
NCT07105111 A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With… Phase4 Schizophrenia Recruiting 2025-08-29 2027-01-01 ClinicalTrials.gov
NCT07196501 A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Trea… Phase3 Major Depressive Disorder Recruiting 2025-08-18 2028-07-01 ClinicalTrials.gov
NCT07105098 NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizop… Phase3 Schizophrenia Recruiting 2025-08-11 2027-11-01 ClinicalTrials.gov
NCT07114874 NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizop… Phase3 Schizophrenia Recruiting 2025-07-11 2031-12-01 ClinicalTrials.gov
NCT06963021 NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as … Phase3 Major Depressive Disorder Recruiting 2025-05-30 2027-07-01 ClinicalTrials.gov
NCT06963034 NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizop… Phase3 Schizophrenia Recruiting 2025-05-08 2027-10-01 ClinicalTrials.gov
NCT06966401 Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adju… Phase3 Major Depressive Disorder Recruiting 2025-04-16 2030-05-01 ClinicalTrials.gov
NCT06911112 NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as … Phase3 Major Depressive Disorder Recruiting 2025-03-31 2027-07-01 ClinicalTrials.gov
NCT06786624 Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatme… Phase3 Major Depressive Disorder Recruiting 2025-01-22 2027-07-01 ClinicalTrials.gov
NCT06107829 Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Develop… Phase4 Tardive Dyskinesia Withdrawn 2025-01-01 2027-02-01 ClinicalTrials.gov
NCT05053321 Reduction of Demoralization in Patients With Tardive Dyskinesia After Treatment… Phase1 Tardive Dyskinesia Withdrawn 2024-10-18 2025-10-18 ClinicalTrials.gov
NCT06312189 Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participa… Phase3 Chorea, Huntington Enrolling_By_Invitation 2024-04-24 2026-04-01 ClinicalTrials.gov
NCT06267846 A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major… Phase2 Major Depressive Disorder Completed 2024-03-20 2025-09-11 ClinicalTrials.gov
NCT05207085 Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults Phase2 Trichotillomania (Hair-Pulling Disorder) Recruiting 2024-02-02 2027-02-15 ClinicalTrials.gov
NCT05859698 Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Ou… Phase4 Schizophrenia Completed 2023-05-09 2024-12-27 ClinicalTrials.gov
NCT05654870 Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an A… Phase3 Schizophrenia Terminated 2023-01-05 2023-11-08 ClinicalTrials.gov
NCT05493293 Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used… Phase2 Focal Onset Seizure Terminated 2022-11-09 2024-03-11 ClinicalTrials.gov
NCT05545111 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults W… Phase2 Schizophrenia Completed 2022-10-04 2024-07-10 ClinicalTrials.gov
NCT05226780 Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjuncti… Phase2 SCN8A Developmental and Epileptic Encephalopathy Syndrome Terminated 2022-07-12 2025-11-12 ClinicalTrials.gov
NCT05301894 Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic… Phase2 Epileptic Encephalopathy Terminated 2022-06-07 2025-01-27 ClinicalTrials.gov
NCT05063994 Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in … Phase3 Congenital Adrenal Hyperplasia Completed 2022-05-24 2024-02-02 ClinicalTrials.gov
NCT06060444 Evaluating a Telemedicine Neurological Consult Program for Drug-Induced Movemen… Na Drug-Induced Movement Disorder Completed 2022-04-26 2024-10-31 ClinicalTrials.gov
NCT05206513 Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the T… Phase3 Dyskinesia Completed 2022-04-15 2026-03-31 ClinicalTrials.gov
NCT05299554 Long-term Safety Study of Chronocort in the Treatment of Participants With Cong… Phase3 Congenital Adrenal Hyperplasia Completed 2022-04-01 2026-01-15 ClinicalTrials.gov
NCT05203341 Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Dep… Phase2 Major Depressive Disorder Completed 2022-02-21 2024-02-21 ClinicalTrials.gov
NCT04873869 Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Devel… Phase2 SCN8A Developmental and Epileptic Encephalopathy Syndrome Terminated 2022-01-31 2023-03-17 ClinicalTrials.gov
NCT05182476 Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Par… Phase2 Schizophrenia Terminated 2021-12-07 2024-10-14 ClinicalTrials.gov
NCT05165394 Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in th… Phase2 Anhedonia Completed 2021-11-30 2023-09-13 ClinicalTrials.gov
NCT05110157 Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine a… Phase3 Schizophrenia Completed 2021-11-29 2025-02-18 ClinicalTrials.gov
NCT05222152 Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insuffic… Phase2 Primary Adrenal Insufficiency Completed 2021-11-23 2023-10-18 ClinicalTrials.gov
NCT05159908 A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is… Phase2 Focal Onset Seizure Completed 2021-11-08 2023-08-21 ClinicalTrials.gov
NCT04806451 Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Part… Phase3 Congenital Adrenal Hyperplasia Active_Not_Recruiting 2021-06-25 2027-08-01 ClinicalTrials.gov
NCT04625101 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric… Phase2 Epileptic Encephalopathy Completed 2021-04-26 2022-10-11 ClinicalTrials.gov
NCT04880616 Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential… Phase2 Essential Tremor Completed 2021-04-20 2022-06-08 ClinicalTrials.gov
NCT04787965 Opicapone Treatment Initiation Open-Label Study — Parkinson Disease Completed 2021-03-01 2022-08-04 ClinicalTrials.gov
NCT04490915 Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Ad… Phase3 Congenital Adrenal Hyperplasia Active_Not_Recruiting 2020-12-16 2027-08-01 ClinicalTrials.gov
NCT04400331 Open-Label Rollover Study for Continuing Valbenazine Administration for the Tre… Phase3 Chorea, Huntington Active_Not_Recruiting 2020-09-18 2026-03-01 ClinicalTrials.gov
NCT04234672 A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize… Phase1 Healthy Volunteers Completed 2020-02-17 2020-04-04 ClinicalTrials.gov
NCT04045145 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crin… Phase2 CAH - Congenital Adrenal Hyperplasia Completed 2019-12-12 2021-07-02 ClinicalTrials.gov
NCT04102579 Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea A… Phase3 Chorea, Huntington Completed 2019-11-13 2021-10-26 ClinicalTrials.gov
NCT03891862 Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dy… Phase4 Tardive Dyskinesia (TD) Completed 2019-03-18 2020-01-30 ClinicalTrials.gov
NCT03792672 A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TA… Phase1 Healthy Volunteers Completed 2019-02-11 2019-06-18 ClinicalTrials.gov
NCT03706469 A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK… Phase1 Healthy Volunteers Completed 2018-10-18 2018-12-22 ClinicalTrials.gov
NCT03562494 VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1) Phase1 Parkinson's Disease Completed 2018-10-17 2024-10-30 ClinicalTrials.gov
NCT03732534 Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects Wi… Phase2 Tourette Syndrome Terminated 2018-10-17 2019-02-18 ClinicalTrials.gov
NCT03687684 Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects Phase1 Healthy Volunteers Completed 2018-10-09 2019-06-19 ClinicalTrials.gov
NCT03532022 Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement… Phase3 Congenital Adrenal Hyperplasia Withdrawn 2018-10-04 2021-07-09 ClinicalTrials.gov
NCT03698331 The Potential for Clinical Dependence and Withdrawal Symptoms Associated With V… Phase4 Tardive Dyskinesia (TD) Completed 2018-09-14 2019-04-03 ClinicalTrials.gov
NCT03733496 Observational, Long-term Extension Study for Participants of Prior VY-AADC01 St… — Parkinson's Disease Completed 2018-08-24 2023-07-18 ClinicalTrials.gov
NCT03530293 Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome Phase2 Tourette Syndrome Terminated 2018-04-17 2019-07-16 ClinicalTrials.gov
NCT03311932 A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects Phase1 Adrenal Insufficiency Completed 2018-04-16 2018-07-13 ClinicalTrials.gov
NCT03525886 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Ad… Phase2 CAH - Congenital Adrenal Hyperplasia Completed 2018-04-10 2020-04-07 ClinicalTrials.gov
NCT03343327 A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects Phase1 Adrenal Insufficiency Completed 2018-02-19 2018-04-20 ClinicalTrials.gov
NCT03496870 A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in S… Phase1 Parkinson Disease Completed 2018-02-08 2018-07-02 ClinicalTrials.gov
NCT03444038 Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pedi… Phase2 Tourette Syndrome Completed 2018-02-08 2019-07-12 ClinicalTrials.gov
NCT03359785 A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizoph… Phase2 Schizophrenia Completed 2018-01-10 2020-12-21 ClinicalTrials.gov
NCT03382639 A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Sympt… Phase2 Schizophrenia Completed 2018-01-04 2021-01-12 ClinicalTrials.gov
NCT03319953 A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of… Phase2 Stable Schizophrenia Completed 2017-12-21 2019-11-06 ClinicalTrials.gov
NCT03214588 Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 … Phase2 Friedreich Ataxia Completed 2017-11-08 2018-12-27 ClinicalTrials.gov
NCT03325010 Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric … Phase2 Tourette Syndrome Completed 2017-10-05 2018-11-16 ClinicalTrials.gov
NCT03224325 A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Mu… Phase1 Healthy Completed 2017-07-21 2018-09-09 ClinicalTrials.gov
NCT03178214 Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral… Phase1 Adrenal Insufficiency Completed 2017-05-22 2017-07-26 ClinicalTrials.gov
NCT03065192 Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease Phase1 Idiopathic Parkinson's Disease Completed 2017-05-11 2021-08-10 ClinicalTrials.gov
NCT03062033 Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Ta… — Tardive Dyskinesia Unknown 2017-04-04 2018-08-01 ClinicalTrials.gov
NCT03101293 A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Table… Phase1 Healthy Volunteers Completed 2017-04-04 2017-05-26 ClinicalTrials.gov
NCT02959892 A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect … Phase1 Healthy Volunteers Completed 2016-12-05 2017-08-23 ClinicalTrials.gov
NCT02966652 Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonad… Phase1 Male Hypogonadism Completed 2016-11-03 2018-10-04 ClinicalTrials.gov
NCT02879578 Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With T… Phase2 Tourette Syndrome Completed 2016-07-25 2017-11-01 ClinicalTrials.gov
NCT02736955 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Tr… Phase3 Tardive Dyskinesia Completed 2016-06-13 2017-06-30 ClinicalTrials.gov
NCT02748694 Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study Phase1 Healthy Volunteers Completed 2016-05-09 2019-09-22 ClinicalTrials.gov
NCT02679079 Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourett… Phase2 Tourette Syndrome Completed 2016-03-23 2017-04-14 ClinicalTrials.gov
NCT02716987 Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After… Phase1 Healthy Completed 2016-03-21 2016-08-30 ClinicalTrials.gov
NCT02733367 Extension Study for Patients Entered Into Study Infacort 003 Phase3 Adrenal Insufficiency Completed 2016-03-04 2018-08-10 ClinicalTrials.gov
NCT02716818 Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With… Phase3 Congenital Adrenal Hyperplasia Completed 2016-02-22 2018-07-28 ClinicalTrials.gov
NCT02581865 Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome Phase2 Tourette Syndrome Completed 2015-11-01 2016-12-01 ClinicalTrials.gov
NCT02566759 A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants Phase1 Schizophrenia, Cerebellar Ataxia Terminated 2015-09-23 2016-07-12 ClinicalTrials.gov
NCT02561156 TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants Phase1 Depressive Disorder Completed 2015-08-26 2017-09-23 ClinicalTrials.gov
NCT02405091 Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskine… Phase3 Tardive Dyskinesia Completed 2015-03-01 2017-03-01 ClinicalTrials.gov
NCT02349503 Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Female… Phase1 Congenital Adrenal Hyperplasia Withdrawn 2015-02-01 2015-10-01 ClinicalTrials.gov
NCT02408068 Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Re… Phase1 Healthy Completed 2015-01-01 2015-03-01 ClinicalTrials.gov
NCT02274558 A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia Phase3 Tardive Dyskinesia Completed 2014-10-01 2016-07-01 ClinicalTrials.gov
NCT02256475 Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Ado… Phase1 Tourette Syndrome Completed 2014-09-01 2015-12-01 ClinicalTrials.gov
NCT01960530 An Investigational Study of Hydrocortisone Phase1 Adrenal Insufficiency Completed 2013-10-01 2014-11-01 ClinicalTrials.gov
NCT01973543 Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease Phase1 Parkinson's Disease Completed 2013-10-01 2020-01-24 ClinicalTrials.gov
NCT01916993 Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Sub… Phase1 Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects Completed 2013-08-01 2013-12-01 ClinicalTrials.gov
NCT01910480 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854… Phase1 Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects Completed 2013-07-01 2013-08-01 ClinicalTrials.gov
NCT01733121 NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia Phase2 Tardive Dyskinesia Completed 2012-12-01 2013-12-01 ClinicalTrials.gov
NCT01735617 Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Ch… Phase2 Endocrine Disease Completed 2012-12-01 2013-12-01 ClinicalTrials.gov
NCT01688037 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophreni… Phase2 Tardive Dyskinesia Completed 2012-09-01 2013-10-01 ClinicalTrials.gov
NCT01393600 NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophreni… Phase2 Tardive Dyskinesia Completed 2011-08-01 2012-02-01 ClinicalTrials.gov
NCT01403038 An Open-label Study of the Effects of Elagolix in Adult Premenopausal Females Phase1 Folliculogenesis Completed 2011-06-01 2012-11-01 ClinicalTrials.gov
NCT03051893 A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of u… Phase1 Adrenal Insufficiency Completed 2011-02-01 2012-04-01 ClinicalTrials.gov
NCT01267188 Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia Phase2 Tardive Dyskinesia Completed 2011-01-01 2011-03-01 ClinicalTrials.gov
NCT03019614 An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortis… Phase1 Congenital Adrenal Hyperplasia Completed 2010-03-01 2010-04-01 ClinicalTrials.gov
NCT00525941 An Exploratory Study of NBI-34060 Capsules and Next Day Functioning Phase3 Insomnia Withdrawn 2007-09-01 2008-01-01 ClinicalTrials.gov
NCT00232167 Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depressi… Phase3 Insomnia Terminated 2005-11-01 2006-04-01 ClinicalTrials.gov
NCT00039052 Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurren… Phase1 Breast Cancer Completed 2002-01-01 2008-07-01 ClinicalTrials.gov
NCT00873561 A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of… Phase1 Type 1 Diabetes Mellitus Completed 2001-12-01 2006-07-01 ClinicalTrials.gov
NCT00014677 NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma M… Phase2 Brain and Central Nervous System Tumors Completed 2001-03-01 2008-07-01 ClinicalTrials.gov
Total clinical trials: 107
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
Valbenazine Other Phase PHASE4 Schizophrenia RECRUITING NCT07105111
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07114874
exposure to healthcare transition protocol Other Preclinical Congenital Adrenal Hyperplasia NOT_YET_RECRUITING NCT07611786
NBI-921352 Other Phase PHASE2 SCN8A Developmental and Epileptic Encephalopathy Syndrome TERMINATED NCT05226780
NBI-921352 Other Phase PHASE2 SCN8A Developmental and Epileptic Encephalopathy Syndrome TERMINATED NCT05226780
NBI-921352 Other Phase PHASE2 SCN8A Developmental and Epileptic Encephalopathy Syndrome TERMINATED NCT05226780
NBI-921352 Other Phase PHASE2 SCN8A Developmental and Epileptic Encephalopathy Syndrome TERMINATED NCT05226780
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-1117570 Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-921352 Other Phase PHASE2 SCN8A Developmental and Epileptic Encephalopathy Syndrome TERMINATED NCT05226780
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-1117570 Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-921352 Other Phase PHASE2 SCN8A Developmental and Epileptic Encephalopathy Syndrome TERMINATED NCT05226780
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-1117570 Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-921352 Other Phase PHASE2 SCN8A Developmental and Epileptic Encephalopathy Syndrome TERMINATED NCT05226780
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-1117570 Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-1117570 Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-1117570 Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-1117570 Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-1117570 Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-1117570 Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-1117570 Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07114874
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07114874
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07114874
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07114874
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07114874
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07114874
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07114874
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07114874
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Crinecerfont Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Crinecerfont Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Crinecerfont Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Crinecerfont Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Crinecerfont Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Crinecerfont Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Valbenazine Other Phase PHASE4 Schizophrenia RECRUITING NCT07105111
Valbenazine Other Phase PHASE4 Schizophrenia RECRUITING NCT07105111
Valbenazine Other Phase PHASE4 Schizophrenia RECRUITING NCT07105111
Valbenazine Other Phase PHASE4 Schizophrenia RECRUITING NCT07105111
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
NBI-98854 Other Phase PHASE1 Tourette Syndrome COMPLETED NCT02256475
Placebo Other Phase PHASE2 Tardive Dyskinesia COMPLETED NCT01393600
NBI-98854 Other Phase PHASE2 Tardive Dyskinesia COMPLETED NCT01393600
Carbidopa Levodopa Other Phase PHASE1 Parkinson Disease COMPLETED NCT03496870
Opicapone Other Phase PHASE1 Parkinson Disease COMPLETED NCT03496870
Infacort® Other Phase PHASE3 Adrenal Insufficiency COMPLETED NCT02733367
[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02959892
TAK -041 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02959892
Amphetamine Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02959892
Placebo oral capsule Other Phase PHASE4 Tardive Dyskinesia (TD) COMPLETED NCT03891862
Valbenazine Other Phase PHASE4 Tardive Dyskinesia (TD) COMPLETED NCT03891862
TAK-831 Suspension Other Phase PHASE1 Healthy COMPLETED NCT03224325
Placebo Other Phase PHASE1 Healthy COMPLETED NCT03224325
TAK-831 Tablet T2 Other Phase PHASE1 Healthy COMPLETED NCT03224325
TAK-831 Placebo Other Phase PHASE2 Friedreich Ataxia COMPLETED NCT03214588
TAK-831 Other Phase PHASE2 Friedreich Ataxia COMPLETED NCT03214588
Valbenazine Oral Capsule Other Phase PHASE4 Tardive Dyskinesia WITHDRAWN NCT06107829
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04806451
Crinecerfont Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04806451
Valbenazine Other Phase PHASE1 Tardive Dyskinesia WITHDRAWN NCT05053321
NBI-98854 Other Phase PHASE2 Tardive Dyskinesia COMPLETED NCT01267188
elagolix Other Phase PHASE1 Folliculogenesis COMPLETED NCT01403038
Elagolix Other Phase PHASE1 Folliculogenesis COMPLETED NCT01403038
Ketoconazole 400 mg (200 mg twice daily) Other Phase PHASE1 Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects COMPLETED NCT01910480
NBI-98854 50 mg capsule once daily Other Phase PHASE1 Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects COMPLETED NCT01910480
NBI-98854 50 mg capsule Other Phase PHASE1 Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects COMPLETED NCT01916993
NBI-77860 Other Phase PHASE1 Congenital Adrenal Hyperplasia WITHDRAWN NCT02349503
Chronocort Other Phase PHASE1 Congenital Adrenal Hyperplasia COMPLETED NCT03019614
Hydrocortisone Other Phase PHASE1 Congenital Adrenal Hyperplasia COMPLETED NCT03019614
Chronocort Other Phase PHASE1 Congenital Adrenal Hyperplasia COMPLETED NCT03019614
Hydrocortisone Other Phase PHASE1 Congenital Adrenal Hyperplasia COMPLETED NCT03019614
Chronocort Other Phase PHASE1 Congenital Adrenal Hyperplasia COMPLETED NCT03019614
Hydrocortisone Other Phase PHASE1 Congenital Adrenal Hyperplasia COMPLETED NCT03019614
Chronocort Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03051893
Chronocort Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03051893
Hydrocortisone Modified Release Capsules Other Phase PHASE2 Endocrine Disease COMPLETED NCT01735617
Hydrocortisone Modified Release Capsules Other Phase PHASE2 Endocrine Disease COMPLETED NCT01735617
Hydrocortisone Modified Release Capsules Other Phase PHASE2 Endocrine Disease COMPLETED NCT01735617
Placebo Other Phase PHASE3 Tardive Dyskinesia COMPLETED NCT02274558
NBI-98854 Other Phase PHASE3 Tardive Dyskinesia COMPLETED NCT02274558
Placebo Other Phase PHASE2 Tardive Dyskinesia COMPLETED NCT01733121
NBI-98854 Other Phase PHASE2 Tardive Dyskinesia COMPLETED NCT01733121
Placebo Other Phase PHASE2 Tardive Dyskinesia COMPLETED NCT01688037
NBI-98854 Other Phase PHASE2 Tardive Dyskinesia COMPLETED NCT01688037
Infacort Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03178214
Infacort Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03178214
NBI-98854 Other Phase PHASE3 Tardive Dyskinesia COMPLETED NCT02405091
Valbenazine Other Phase PHASE3 Tardive Dyskinesia COMPLETED NCT02736955
Cortef® Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03311932
Infacort® Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03311932
Cortef® Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03311932
Infacort® Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03311932
Infacort® Other Phase PHASE3 Adrenal Insufficiency COMPLETED NCT02733367
Testosterone undecanoate Other Phase PHASE1 Male Hypogonadism COMPLETED NCT02966652
DITEST Other Phase PHASE1 Male Hypogonadism COMPLETED NCT02966652
VY-AADC01 Other Phase PHASE1 Parkinson's Disease COMPLETED NCT01973543
Placebo Other Phase PHASE2 Tourette Syndrome COMPLETED NCT02581865
NBI-98854 Other Phase PHASE2 Tourette Syndrome COMPLETED NCT02581865
Placebo oral capsule Other Phase PHASE4 Tardive Dyskinesia (TD) COMPLETED NCT03698331
Valbenazine Other Phase PHASE4 Tardive Dyskinesia (TD) COMPLETED NCT03698331
Cortef® Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03343327
Chronocort® Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03343327
Placebo Other Phase PHASE2 Tourette Syndrome COMPLETED NCT02679079
NBI-98854 Other Phase PHASE2 Tourette Syndrome COMPLETED NCT02679079
TAK-653 Other Phase PHASE1 Depressive Disorder COMPLETED NCT02561156
TAK-653 Placebo Other Phase PHASE1 Depressive Disorder COMPLETED NCT02561156
Ketamine Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03792672
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03792672
TAK-653 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03792672
Second Generation Antipsychotics (SGA) Other Phase PHASE2 Stable Schizophrenia COMPLETED NCT03319953
Placebo Other Phase PHASE2 Stable Schizophrenia COMPLETED NCT03319953
TAK-041 Other Phase PHASE2 Stable Schizophrenia COMPLETED NCT03319953
TAK-041 Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02748694
TAK-041 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT02748694
Valbenazine Other Phase PHASE2 Tourette Syndrome COMPLETED NCT02879578
standard glucocorticoid therapy Drug Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT02716818
Chronocort® Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT02716818
standard glucocorticoid therapy Drug Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT02716818
Chronocort® Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT02716818
TAK-831 T3 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03706469
TAK-831 T2 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03706469
Placebo Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03687684
TAK-831 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03687684
TAK-831 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT03101293
[18F]PGM299 Other Phase PHASE1 Healthy COMPLETED NCT02716987
TAK-831 Other Phase PHASE1 Healthy COMPLETED NCT02716987
TAK-831 Tablet Other Phase PHASE1 Schizophrenia, Cerebellar Ataxia TERMINATED NCT02566759
TAK-831 Placebo Other Phase PHASE1 Schizophrenia, Cerebellar Ataxia TERMINATED NCT02566759
TAK-831 Oral Suspension Other Phase PHASE1 Schizophrenia, Cerebellar Ataxia TERMINATED NCT02566759
Placebo oral capsule Other Phase PHASE2 Tourette Syndrome COMPLETED NCT03325010
Valbenazine Other Phase PHASE2 Tourette Syndrome COMPLETED NCT03325010
[14C]TAK-831 Oral Suspension Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04234672
[14C]TAK-831 IV Infusion Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04234672
TAK-831 Oral Tablet Other Phase PHASE1 Healthy Volunteers COMPLETED NCT04234672
Valbenazine Other Phase PHASE2 Tourette Syndrome COMPLETED NCT03444038
VY-AADC01 Other Phase PHASE1 Idiopathic Parkinson's Disease COMPLETED NCT03065192
Standard Care Other Phase PHASE3 Congenital Adrenal Hyperplasia WITHDRAWN NCT03532022
Chronocort® Other Phase PHASE3 Congenital Adrenal Hyperplasia WITHDRAWN NCT03532022
Standard Care Other Phase PHASE3 Congenital Adrenal Hyperplasia WITHDRAWN NCT03532022
Chronocort® Other Phase PHASE3 Congenital Adrenal Hyperplasia WITHDRAWN NCT03532022
Standard Care Other Phase PHASE3 Congenital Adrenal Hyperplasia WITHDRAWN NCT03532022
Chronocort® Other Phase PHASE3 Congenital Adrenal Hyperplasia WITHDRAWN NCT03532022
NBI-98854 Other Phase PHASE2 Tourette Syndrome TERMINATED NCT03732534
Dexamethasone Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT01960530
i.v. Hydrocortisone Injection Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT01960530
Hydrocortisone Tablet Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT01960530
Hydrocortisone granules Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT01960530
Dexamethasone Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT01960530
i.v. Hydrocortisone Injection Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT01960530
Hydrocortisone Tablet Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT01960530
Hydrocortisone granules Other Phase PHASE1 Adrenal Insufficiency COMPLETED NCT01960530
NBI-74788 Other Phase PHASE2 CAH - Congenital Adrenal Hyperplasia COMPLETED NCT03525886
Chronocort: fed Other Phase PHASE1 Healthy COMPLETED NCT02408068
Immediate release hydrocortisone: fasted Other Phase PHASE1 Healthy COMPLETED NCT02408068
Chronocort: fasted Other Phase PHASE1 Healthy COMPLETED NCT02408068
Dexamethasone Other Phase PHASE1 Healthy COMPLETED NCT02408068
Chronocort: fed Other Phase PHASE1 Healthy COMPLETED NCT02408068
Immediate release hydrocortisone: fasted Other Phase PHASE1 Healthy COMPLETED NCT02408068
Chronocort: fasted Other Phase PHASE1 Healthy COMPLETED NCT02408068
Dexamethasone Other Phase PHASE1 Healthy COMPLETED NCT02408068
Placebo oral capsule Other Phase PHASE2 Tourette Syndrome TERMINATED NCT03530293
Valbenazine Other Phase PHASE2 Tourette Syndrome TERMINATED NCT03530293
Placebo Other Phase PHASE2 Essential Tremor COMPLETED NCT04880616
NBI-827104 Other Phase PHASE2 Essential Tremor COMPLETED NCT04880616
Opicapone Other Preclinical Parkinson Disease COMPLETED NCT04787965
Placebo Other Phase PHASE3 Chorea, Huntington COMPLETED NCT04102579
Valbenazine Other Phase PHASE3 Chorea, Huntington COMPLETED NCT04102579
Placebo Other Phase PHASE2 Schizophrenia COMPLETED NCT03382639
Luvadaxistat Other Phase PHASE2 Schizophrenia COMPLETED NCT03382639
Matching Placebo Other Phase PHASE2 Schizophrenia COMPLETED NCT03359785
Luvadaxistat Other Phase PHASE2 Schizophrenia COMPLETED NCT03359785
NBI-921352 Other Phase PHASE2 Focal Onset Seizure TERMINATED NCT05493293
Plenadren Other Phase PHASE2 Primary Adrenal Insufficiency COMPLETED NCT05222152
Chronocort Other Phase PHASE2 Primary Adrenal Insufficiency COMPLETED NCT05222152
Plenadren Other Phase PHASE2 Primary Adrenal Insufficiency COMPLETED NCT05222152
Chronocort Other Phase PHASE2 Primary Adrenal Insufficiency COMPLETED NCT05222152
Crinecerfont Other Phase PHASE2 CAH - Congenital Adrenal Hyperplasia COMPLETED NCT04045145
NBI-1065846 Other Phase PHASE2 Anhedonia COMPLETED NCT05165394
Placebo Other Phase PHASE2 Anhedonia COMPLETED NCT05165394
Placebo Other Phase PHASE2 Focal Onset Seizure COMPLETED NCT05159908
NBI-921352 Other Phase PHASE2 Focal Onset Seizure COMPLETED NCT05159908
In-person Consult Other Approved Drug-Induced Movement Disorder COMPLETED NCT06060444
Telemedicine Consult Other Approved Drug-Induced Movement Disorder COMPLETED NCT06060444
Placebo Other Phase PHASE3 Schizophrenia TERMINATED NCT05654870
Valbenazine Other Phase PHASE3 Schizophrenia TERMINATED NCT05654870
Sham (Placebo) Surgery Procedure Phase PHASE1 Parkinson's Disease COMPLETED NCT03562494
VY-AADC02 Other Phase PHASE1 Parkinson's Disease COMPLETED NCT03562494
Valbenazine Other Phase PHASE3 Chorea, Huntington ACTIVE_NOT_RECRUITING NCT04400331
NBI-1065845 Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT05203341
Placebo Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT05203341
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Crinecerfont Other Phase PHASE3 Congenital Adrenal Hyperplasia ACTIVE_NOT_RECRUITING NCT04490915
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT05063994
Cortef Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT05063994
Chronocort Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT05063994
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT05063994
Cortef Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT05063994
Chronocort Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT05063994
Placebo Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT05063994
Cortef Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT05063994
Chronocort Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT05063994
Luvadaxistat Other Phase PHASE2 Schizophrenia TERMINATED NCT05182476
Placebo Other Phase PHASE2 Schizophrenia TERMINATED NCT05182476
Placebo Other Phase PHASE2 Schizophrenia COMPLETED NCT05545111
NBI-1117568 Other Phase PHASE2 Schizophrenia COMPLETED NCT05545111
NBI-921352 Other Phase PHASE2 SCN8A Developmental and Epileptic Encephalopathy Syndrome ACTIVE_NOT_RECRUITING NCT05226780
Placebo Other Phase PHASE2 Epileptic Encephalopathy COMPLETED NCT04625101
NBI-827104 Other Phase PHASE2 Epileptic Encephalopathy COMPLETED NCT04625101
NBI-827104 Other Phase PHASE2 Epileptic Encephalopathy TERMINATED NCT05301894
Placebo Other Phase PHASE2 SCN8A Developmental and Epileptic Encephalopathy Syndrome TERMINATED NCT04873869
NBI-921352 Other Phase PHASE2 SCN8A Developmental and Epileptic Encephalopathy Syndrome TERMINATED NCT04873869
Placebo Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06786624
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06786624
Placebo Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT06267846
NBI-1070770 Other Phase PHASE2 Major Depressive Disorder COMPLETED NCT06267846
Placebo Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06911112
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06911112
Valbenazine Other Phase PHASE4 Schizophrenia COMPLETED NCT05859698
Placebo Oral capsule Other Phase PHASE2 Trichotillomania (Hair-Pulling Disorder) RECRUITING NCT05207085
Valbenazine Oral Capsule Other Phase PHASE2 Trichotillomania (Hair-Pulling Disorder) RECRUITING NCT05207085
Chronocort Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT05299554
Chronocort Other Phase PHASE3 Congenital Adrenal Hyperplasia COMPLETED NCT05299554
Placebo Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
Valbenazine Other Phase PHASE3 Schizophrenia COMPLETED NCT05110157
Placebo Other Phase PHASE3 Schizophrenia COMPLETED NCT05110157
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT06963034
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT06963034
Placebo Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT07196501
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT07196501
Crinecerfont Other Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07187375
Placebo Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT07288320
NBI-1117568 Other Phase PHASE2 Bipolar I Disorder RECRUITING NCT07288320
Valbenazine Other Phase PHASE3 Chorea, Huntington ENROLLING_BY_INVITATION NCT06312189
Placebo Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
NBI-1117570 Other Phase PHASE2 Schizophrenia RECRUITING NCT07288333
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07227818
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07114874
Placebo Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
NBI-1117568 Other Phase PHASE3 Schizophrenia RECRUITING NCT07105098
Placebo Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06963021
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06963021
Valbenazine Other Phase PHASE4 Schizophrenia RECRUITING NCT07105111
Crinecerfont Other Phase PHASE2 Congenital Adrenal Hyperplasia NOT_YET_RECRUITING NCT07536269
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Valbenazine Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE3 Dyskinesia COMPLETED NCT05206513
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
Placebo Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065890 Other Phase PHASE2 Tardive Dyskinesia RECRUITING NCT07365462
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
NBI-1065845 Other Phase PHASE3 Major Depressive Disorder RECRUITING NCT06966401
Crinecerfont Other Phase PHASE2 Congenital Adrenal Hyperplasia NOT_YET_RECRUITING NCT07536269
Valbenazine Other Phase PHASE4 Schizophrenia RECRUITING NCT07105111
Valbenazine Other Phase PHASE4 Schizophrenia RECRUITING NCT07105111
Valbenazine Other Phase PHASE4 Schizophrenia RECRUITING NCT07105111
NBI-1065890 DRUG Phase PHASE2 Tardive Dyskinesia NOT_YET_RECRUITING NCT07365462
NBI-1117570 DRUG Phase PHASE2 Schizophrenia NOT_YET_RECRUITING NCT07288333
NBI-1070770 DRUG Phase PHASE2 Major Depressive Disorder COMPLETED NCT06267846
In-person Consult OTHER Approved Drug-Induced Movement Disorder COMPLETED NCT06060444
Telemedicine Consult OTHER Approved Drug-Induced Movement Disorder COMPLETED NCT06060444
NBI-1117568 DRUG Phase PHASE2 Bipolar I Disorder RECRUITING NCT07288320
Placebo Oral capsule OTHER Phase PHASE2 Trichotillomania (Hair-Pulling Disorder) RECRUITING NCT05207085
Valbenazine Oral Capsule DRUG Phase PHASE4 Tardive Dyskinesia WITHDRAWN NCT06107829
NBI-1065845 DRUG Phase PHASE3 Major Depressive Disorder RECRUITING NCT07196501
NBI-1065846 DRUG Phase PHASE2 Anhedonia COMPLETED NCT05165394
NBI-921352 DRUG Phase PHASE2 Focal Onset Seizure TERMINATED NCT05493293
NBI-827104 DRUG Phase PHASE2 Epileptic Encephalopathy TERMINATED NCT05301894
[14C]TAK-831 Oral Suspension DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04234672
[14C]TAK-831 IV Infusion DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04234672
TAK-831 Oral Tablet DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT04234672
Crinecerfont DRUG Phase PHASE2 Congenital Adrenal Hyperplasia RECRUITING NCT07187375
Ketamine DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03792672
TAK-831 T3 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03706469
TAK-831 T2 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03706469
Sham (Placebo) Surgery OTHER Phase PHASE1 Parkinson's Disease COMPLETED NCT03562494
VY-AADC02 BIOLOGICAL Phase PHASE1 Parkinson's Disease COMPLETED NCT03562494
NBI-74788 DRUG Phase PHASE2 CAH - Congenital Adrenal Hyperplasia COMPLETED NCT03525886
Carbidopa Levodopa DRUG Phase PHASE1 Parkinson Disease COMPLETED NCT03496870
Opicapone DRUG Preclinical Parkinson Disease COMPLETED NCT04787965
Matching Placebo DRUG Phase PHASE2 Schizophrenia COMPLETED NCT03359785
Luvadaxistat DRUG Phase PHASE2 Schizophrenia TERMINATED NCT05182476
Chronocort® DRUG Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03343327
Placebo oral capsule DRUG Phase PHASE4 Tardive Dyskinesia (TD) COMPLETED NCT03891862
Second Generation Antipsychotics (SGA) DRUG Phase PHASE2 Stable Schizophrenia COMPLETED NCT03319953
Cortef® DRUG Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03343327
Infacort® DRUG Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03311932
TAK-831 Suspension DRUG Phase PHASE1 Healthy COMPLETED NCT03224325
TAK-831 Tablet T2 DRUG Phase PHASE1 Healthy COMPLETED NCT03224325
Infacort DRUG Phase PHASE1 Adrenal Insufficiency COMPLETED NCT03178214
Testosterone undecanoate DRUG Phase PHASE1 Male Hypogonadism COMPLETED NCT02966652
DITEST DRUG Phase PHASE1 Male Hypogonadism COMPLETED NCT02966652
[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT02959892
TAK -041 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT02959892
Amphetamine DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT02959892
TAK-041 Placebo DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT02748694
TAK-041 DRUG Phase PHASE2 Stable Schizophrenia COMPLETED NCT03319953
Valbenazine DRUG Phase PHASE2 Obsessive-Compulsive Disorder NOT_YET_RECRUITING NCT07111988
[18F]PGM299 DRUG Phase PHASE1 Healthy COMPLETED NCT02716987
TAK-831 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03687684
TAK-831 Tablet DRUG Phase PHASE1 Schizophrenia, Cerebellar Ataxia TERMINATED NCT02566759
TAK-831 Placebo DRUG Phase PHASE2 Friedreich Ataxia COMPLETED NCT03214588
TAK-831 Oral Suspension DRUG Phase PHASE1 Schizophrenia, Cerebellar Ataxia TERMINATED NCT02566759
TAK-653 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT03792672
TAK-653 Placebo DRUG Phase PHASE1 Depressive Disorder COMPLETED NCT02561156
NBI-77860 DRUG Phase PHASE1 Congenital Adrenal Hyperplasia WITHDRAWN NCT02349503
VY-AADC01 DRUG Phase PHASE1 Idiopathic Parkinson's Disease COMPLETED NCT03065192
NBI-98854 50 mg capsule DRUG Phase PHASE1 Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects COMPLETED NCT01916993
Ketoconazole 400 mg (200 mg twice daily) DRUG Phase PHASE1 Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects COMPLETED NCT01910480
NBI-98854 50 mg capsule once daily DRUG Phase PHASE1 Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects COMPLETED NCT01910480
elagolix DRUG Phase PHASE1 Folliculogenesis COMPLETED NCT01403038
Elagolix DRUG Phase PHASE1 Folliculogenesis COMPLETED NCT01403038
Placebo DRUG Phase PHASE2 Tardive Dyskinesia NOT_YET_RECRUITING NCT07365462
NBI-98854 DRUG Phase PHASE2 Tourette Syndrome TERMINATED NCT03732534
NBI-6024 DRUG Phase PHASE1 Type 1 Diabetes Mellitus COMPLETED NCT00873561
NBI-34060 DRUG Phase PHASE3 Insomnia WITHDRAWN NCT00525941
Sertraline DRUG Phase PHASE3 Insomnia TERMINATED NCT00232167
Indiplon DRUG Phase PHASE3 Insomnia TERMINATED NCT00232167
conventional surgery PROCEDURE Phase PHASE2 Brain and Central Nervous System Tumors COMPLETED NCT00014677
interleukin-4 PE38KDEL cytotoxin BIOLOGICAL Phase PHASE1 Breast Cancer COMPLETED NCT00039052
Total products: 481